Project description
A novel anti-metastatic treatment against triple negative breast cancer
Triple negative breast cancer (TNBC) is an aggressive type of breast cancer with great metastatic propensity. TNBC lacks expression of oestrogen receptors, and as such, there are fewer targeted and efficient treatment options. The EU-funded CanceRusolution project has developed a cytostatic drug that targets the cytoskeleton of TNBC cells, halting their metastatic potential and hence their aggressiveness. Researchers plan to test the treatment in an animal model of TNBC and perform pharmacokinetics analysis. Upscaling treatment production to clinical grade will pave the way towards clinical testing of the treatment, with significant ramifications for the future management of TNBC.
Objective
R-nuucell is developing a new drug to treat Triple Negative Breast Cancer (TNBC) for which there is not any specific and efficient treatment in the market, making this disease an unmet clinical need.
The aggressivity of TNBC is due to the easiness of its metastization expanding the cancer through the body inevitably leading to death. So far, we gathered a set of results showing the antimetastatic potential of our new drug which mode of action would, conceptually, be able to eliminate the deadliest feature of cancer cells – their ability to invade and metastasize. This happens because the target of our drug is the cells’ foundation (ie the cytoskeleton). Thus, destroying the cytoskeleton of cells is like shaking the foundations of a house, it will be tumble-down!
With the Women TechEU program we will consolidate the proof-of-concept of the drug’s efficiency against metastases through two sets of in vivo studies in nude mice, and we will start the pre-clinical studies by performing pharmacokinetics (drug absorption, distribution, metabolism and excretion). Also, in view of the natural future development of our drug we will start to develop its synthesis scale-up from the milligram to the multigram scale.
Women TechEU program mentoring and coaching will be also key to consolidate our business plan and to approach partners and investors towards a fundraising Level A in the near future. This level of funding (~1 M€) will enable to finish our pre-clinical studies and place R-nuucell in the position to license its international patent, one of the company’s assets (PT108082B, EA038640B1, EP3227307B1, CN107466297B, JP6726678B2, US15/533,289, under examination on Canada, Brazil and India), to a pharmaceutical company using a “business-to-business” strategy.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
HORIZON.3.2 - European innovation ecosystems
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
HORIZON-CSA - HORIZON Coordination and Support Actions
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) HORIZON-EIE-2021-SCALEUP-01
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
1749-016 Lisboa
Portugal
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.